The treatment of breast cancer has evolved from a basic initial reliance on surgery to a comprehensive treatment model based on evidence-based medical evidence. Specifically, the operation evolved from the earliest extended root cure to the improved root cure. In the 1990s, our country began breast-puffing operations and an exterior lymphomy test. The operation now follows the trend of the world and includes breast-puffing, breast-repair and forward lymphomy tests. From five to ten years behind world standards in the past, it is now almost the same as international integration. For internal medicine treatments, the use of cytone injections was almost 30 years ago, followed by the CMF (cyclophosphate + methamide + fluorine) programme, followed by cystals and pheasus. The molecular stratification of breast cancer and the introduction of target-oriented drugs are now a concept of comprehensive treatment. Targeting drugs are a milestone in the history of breast cancer treatment, and the trato-chorus resistance to Sher2-positive breast cancer, the Patto-jole resistance, Lapatini, Nadini, and our own national research and development of lyconi have significantly improved the long-term survival of Her2-positive breast cancer patients, turning breast cancer into a chronic, manageable disease! There have also been significant developments in other areas, such as endocrinology treatment, which began in the 1970s and 1980s, and his first half-year, one-and-a-half-year treatment, which has now been updated to five and ten years. Endocrine treatment drugs are also developing, such as ovarian functional inhibitors, combined target drugs – CDK4/6 inhibitors, and estrogen receptors – fluoride swarms, aromatic enzymes inhibitors, etc., which greatly enrich endocrine treatment, make breast cancer treatment easier and more effective in the long term.
Precision medicine and artificial intelligence are two main directions for the future treatment of breast cancer. Precision medicine is evidenced by evidence-based medicine and groupized treatment. There are different types of triple-negative breast cancer, such as those with a BRCA gene mutation, which can be treated with Orapani and platinum, and microsatellites, which can be treated with PD-1, PD-L1 antibodies, which are subject to genetic testing. In the future, what is more precise is an in-depth study of breast cancer. Genetic tests can also be used to predict the risk of re-emergence of diseases, such as the current 21 genes, 50 genes, 70 genes, etc., and our countries are also developing their own pre- and post-risk models for breast cancer. It can predict the risk of re-emergence of breast cancer, with some intensive treatment for those at high risk of recurrence, which is a development of precision medicine. In the Internet+ era, artificial intelligence is more of a development orientation. The artificial intelligence decision-making support system developed on the basis of the CSCO BC is a very terrestrial system. It is based on the CSCO BC guidelines and is aimed at young doctors, doctors in primary hospitals or non-oncological doctors. As long as the basic data of the patients are entered, the treatment provided is in line with the CSCO guidelines, which are almost at the level of a highly qualified doctor who has worked for more than 15 years. If widely applied, the level of treatment in primary hospitals and non-oncological doctors will be greatly improved, thereby increasing the overall long-term survival of breast cancer patients and further improving the overall level of care for breast cancer in the country.
